作者：
Burke, John M. [1]
;
van der Jagt, Richard H. C. [2]
;
Kahl, Brad S. [3]
;
Wood, Peter [4]
;
Hawkins, Tim E. [5]
;
MacDonald, David [6]
;
Hertzberg, Mark [7]
;
Simpson, David [8]
;
Craig, Michael [9]
;
Kolibaba, Kathryn [10]
;
Issa, Samar [11]
;
Munteanu, Mihaela [12]
;
Victor, Timothy W. [13]
;
Flinn, Ian W.
作者单位：
Sarah Cannon Res Inst, Blood Canc Res Program, Nashville, TN USA
[1]
Westmead Hosp, Dept Haematol, Westmead, NSW, Australia
[2]
W Virginia Univ, Dept Med, Sect Hematol Oncol, Morgantown, WV 26506 USA
[3]
Teva Branded Pharmaceut Prod R&D Inc, Clin Res & Dev, New Therapeut Ent, Frazer, PA USA
[4]
McKesson Specialty Hlth, US Oncol Res, The Woodlands, TX USA
[5]
Kantar Hlth, Sci & Strategy, Princeton, NJ USA
[6]
Univ Ottawa, Dept Med, Div Hematol, Ottawa, ON, Canada
[7]
Princess Alexandra Hosp, Dept Haematol, Woolloongabba, Qld, Australia
[8]
North Shore Hosp, Dept Haematol, Takapuna, New Zealand
[9]
Middlemore Hosp, Dept Haematol, Auckland 6, New Zealand
[10]
Univ Wisconsin, Dept Med, Carbone Canc Ctr, Div Hematol Oncol, Madison, WI USA
[11]
Auckland Hosp, Dept Haematol, Auckland, New Zealand
[12]
Dalhousie Univ, Dept Med, Div Hematol, Halifax, NS, Canada
[13]
发布时间
2017-04-06
换一批
